Biopharmx (NYSEAMERICAN:BPMX) has been given a $3.00 price objective by research analysts at Maxim Group in a research report issued on Wednesday, TipRanks reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s target price indicates a potential upside of 253.44% from the company’s previous close.
Shares of NYSEAMERICAN BPMX opened at $0.85 on Wednesday. Biopharmx has a one year low of $0.81 and a one year high of $6.75.
Biopharmx (NYSEAMERICAN:BPMX) last issued its earnings results on Tuesday, June 11th. The biotechnology company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.12).
An institutional investor recently raised its position in Biopharmx stock. Deutsche Bank AG lifted its stake in shares of Biopharmx Corp (NYSEAMERICAN:BPMX) by 1,256.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 549,973 shares of the biotechnology company’s stock after acquiring an additional 509,430 shares during the quarter. Deutsche Bank AG owned about 0.25% of Biopharmx worth $59,000 as of its most recent filing with the SEC.
Biopharmx Company Profile
BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).
Further Reading: The Role of a Fiduciary and Individual Investors
Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.